Bryan Johnson’s Longevity Protocol
About Bryan Johnson
Evidence Rating Key
๐ The Core Question: Do the Supplements Actually Matter?
Johnson’s protocol combines three categories of intervention: sleep (8:30 pm bedtime, 8 hours minimum), exercise (1 hour/day structured training), and 100+ supplements. The critical โ and mostly unasked โ question is: how much of his documented improvement comes from each?
The scientific literature is fairly clear on this hierarchy. Sleep and exercise are the two most powerful known interventions for biological age markers. Regular vigorous exercise alone reduces all-cause mortality risk by 26โ31% per Johnson’s own cited research. Consistent sleep reduces every major disease risk category. These effects are massive, dose-responsive, and free.
Johnson’s supplement stack โ even the most evidence-backed portions โ produce effects measured in percentage points or single biomarker improvements. The fundamental confound: as a single case study simultaneously implementing 100+ interventions, there is no way to isolate supplement contribution. Many experts (including clinicians at ACSH) note this limitation explicitly.1
๐ Protocol Evolution: Then vs Now
Blueprint has changed significantly since 2021. Some changes reflect evidence-based pruning; others coincide with the launch of commercial Blueprint products โ a distinction worth noting.
| Intervention | 2021โ2023 Status | 2024โ2026 Status | Reason for Change |
|---|---|---|---|
| Young plasma transfusions | Active โ receiving son’s plasma | โ Discontinued | No measurable effect on biomarkers; team data analysis concluded no benefit |
| Growth Hormone (GH) | Active (100-day trial) | โ Discontinued | Side effects: elevated intracranial pressure, headaches, blood glucose spike2 |
| Rapamycin | Active (weekly) | โ Discontinued 2024 | Side effects; concluded it “may have done more harm than good”3 |
| Cerebrolysin (injections) | Active (3-month trial) | โ Discontinued | No measurable cognitive biomarker effect found |
| Metformin | Active (longevity use) | โ ๏ธ Reduced / personal | Concerns about blunting exercise adaptations (mitochondrial signalling) |
| Acarbose (Rx) | Active | โ Still active (200 mg/day) | Continued โ post-meal glucose blunting, ITP animal data |
| NMN / NR (NAD+) | Active | โ Active โ alternating NMN/NR 6x/week | Cornerstone โ also sold in Blueprint commercial stack |
| HBOT (hyperbaric Oโ) | Not in protocol | โ Added Nov 2024 โ 60 sessions at 2 ATA | Telomere extension results, inflammation elimination (hsCRP undetectable) |
| Gene Therapy (Follistatin) | Not in protocol | โ Added Oct 2023 โ ongoing | 160% follistatin increase reported; muscle preservation / myostatin inhibition |
๐ฐ The Commercial Blueprint: Protocol or Product?
Starting in 2023, Johnson launched Blueprint-branded supplements (Essential Capsules, Longevity Mix, Protein powder, Olive Oil, etc.). This creates an important distinction that many followers miss:
- Johnson’s personal stack: 100+ compounds including Rx drugs (Acarbose, Tadalafil), gene therapy, HBOT, plasmalogens โ supervised by 30 doctors, costs millions
- Commercial Blueprint products: Simplified OTC versions (NMN, Vitamin C, Niacinamide, Omega-3, polyphenols) โ priced accessibly, sold to the public
- The gap: The compounds Johnson actually attributes his results to (Acarbose, HBOT, gene therapy) are not available in his commercial products by definition
- The incentive: Johnson’s public emphasis has increasingly shifted toward supplements included in his commercial stack โ a conflict of interest worth weighing when evaluating his recommendations
This is not unique to Johnson โ most longevity influencers who sell supplements face the same tension. Blueprint markets its products at “near not-for-profit pricing”, though independent verification of this claim is not available.
Evidence Ratings
โ โ โ โ โ Good evidence
โ โ โ โโ Moderate/mixed
โ โ โโโ Weak/anecdotal
โ โโโโ Experimental only
๐ Current Core Supplements (2025โ2026)
| Supplement | Dose | Purpose | Evidence | In Blueprint Product? |
|---|---|---|---|---|
| NMN / NR (alternating) | 500โ1,000 mg/day, 6x/week | NAD+ restoration; mitochondrial energy | โ โ โ โโ | โ Yes |
| Vitamin D3 + K2 | 2,000โ4,000 IU D3 / 180 mcg K2-MK7 | Immune, bone, cardiovascular; both K forms (MK-4 + MK-7) | โ โ โ โ โ | โ Yes |
| Omega-3 (DHA/EPA) | 1,000โ2,000 mg/day | Cardiovascular, inflammation, brain | โ โ โ โ โ | โ Yes (Blueprint DHA/EPA) |
| Vitamin C | 500 mg/day | Antioxidant; collagen synthesis; immune | โ โ โ โ โ | โ Yes |
| Niacinamide (B3) | 300 mg/day | NAD+ support; DNA repair; skin health | โ โ โ โ โ | โ Yes |
| Spermidine | 1 mg/day (wheat germ or supplement) | Autophagy induction; anti-senescence | โ โ โ โโ | โ Yes |
| Calcium AKG (Ca-AKG) | 1,000 mg/day | Krebs cycle; epigenetic clock; lifespan in animal studies | โ โ โ โโ | โ Yes |
| Lycopene | 10 mg/day | Prostate protection; cardiovascular antioxidant | โ โ โ โ โ | Partial |
| Ashwagandha | 600 mg/day (KSM-66) | Cortisol regulation; sleep quality; stress resilience | โ โ โ โ โ | Partial |
| CoQ10 (Ubiquinol) | 100 mg/day | Mitochondrial electron transport chain | โ โ โ โ โ | Partial |
๐ฌ Prescription & Experimental (Not in Commercial Products)
| Intervention | Type | Purpose | Evidence |
|---|---|---|---|
| Acarbose | Rx drug | Post-meal glucose blunting; ITP longevity data (animal) | โ โ โ โ โ |
| Tadalafil | Rx drug | Endothelial function; cardiovascular; inflammation4 | โ โ โ โโ |
| HBOT (60 sessions) | Experimental | Telomere extension; senolytic; inflammation reset | โ โ โ โโ |
| Gene Therapy (Follistatin) | Experimental | Myostatin inhibition; muscle mass; anti-aging (animal data) | โ โ โโโ |
| Plasmalogens (Glia/Neuro) | Experimental | Brain/heart phospholipids; antioxidant; cognitive longevity | โ โ โโโ |
| MSC Stem Cells (300M) | Experimental | Joint regeneration; injected knees/hips/shoulders Mar 2024 | โ โโโโ |
๐ Results: Johnson vs Peers vs US Averages
Johnson publishes biomarker data publicly. Below we compare his reported markers against available data from other longevity influencers and US reference ranges โ adding context rather than just presenting his claims.
| Marker | Johnson (2025) | US Average (47yo male) | Attia (similar age) | Notes |
|---|---|---|---|---|
| hsCRP (inflammation) | <0.1 mg/L (undetectable) | ~1.5โ2.5 mg/L | Typically <0.5 mg/L | Post-HBOT. Previously ~0.3โ0.5. HBOT likely major contributor. |
| Biological age (epigenetic) | ~35โ38 (claimed) | ~47 (matches chrono) | Not published | Claims 5+ yr reversal. Epigenetic clocks have ยฑ2โ3yr error. Methodology varies by clock used.5 |
| Telomere length | 10.3โ11.4 kb (post-HBOT) | ~7โ8 kb (47yo) | Not published | Baseline already “10-year-old equivalent.” 2.6% extension notable โ or ceiling effect. Single measurement. |
| VOโ max | ~67 mL/kg/min | ~35โ38 (average 47yo) | ~60+ (elite athlete range) | This is almost certainly exercise-driven. Matches elite cyclist/runner performance. |
| Skin age reversal | โ9 years (claimed) | N/A | N/A | Measured via Canfield Visia multispectral imaging. UV protection + Blueprint skincare products + red light โ not supplements alone. |
| Intracellular NAD+ | 54.6 ฮผM (optimal range) | ~20โ40 ฮผM (declines with age) | Not published | Tested via Jinfiniti assay. NMN/NR supplementation likely contributor. Exercise also raises NAD+. |
๐ Lifestyle: The Underrated Core
Johnson’s lifestyle protocols are likely his highest-leverage interventions. They are free, evidence-based, and poorly promoted compared to his supplement stack โ possibly because they cannot be commercialised.
โ โ โ โ โ
Rigid consistency: same bedtime nightly, no screens 60 min before. Johnson calls this “the most heroic act in 2025.” The evidence agrees: consistent sleep timing is at least as important as duration for cardiovascular and metabolic outcomes.6
โ โ โ โ โ
Mix of Zone 2 cardio and resistance training. His own cited literature: regular exercise reduces all-cause mortality by 26โ31% and cardiovascular disease by 28โ38%.7 His VOโ max of ~67 is the single most striking biomarker in his data โ and the most exercise-attributable.
โ โ โ โ โ
All food consumed within a 6โ8 hour window. 100g protein minimum. Minimal processing, high fibre (โฅ30g/day). Zero alcohol. This dietary pattern alone has decades of strong outcome data in longevity literature.
Footnotes
- American Council on Science and Health (ACSH), 2025: “Case studies represent the lowest level of scientific evidence. There is no way to guarantee which specific interventions produced Johnson’s results.”
- Growth hormone discontinued after 100-day trial. Side effects: elevated intracranial pressure, headaches, blood glucose spike. Source: protocol.bryanjohnson.com
- Rapamycin: Johnson’s 2024 statement โ decided it “may have done more harm than good.” Contrast with Attia and Sinclair who still advocate for rapamycin. See Attia protocol page.
- Tadalafil (2.5 mg daily) โ endothelial function use, not traditional indication. Off-label longevity use increasingly studied; not FDA-approved for this indication.
- Epigenetic clocks (Horvath, DunedinPace, GrimAge) have measurement error of ยฑ2โ3 years. “Biological age reversal” claims depend heavily on which clock is used and baseline variation.
- Walker MP. “Why We Sleep.” 2017. Sleep consistency evidence: Chellappa et al., PNAS, 2021.
- Ortega FB et al. BMJ, 2012. ~1.1M Swedish adolescent males: weakest tertile muscular strength โ 20โ35% higher premature death risk vs strongest tertile.
Changelog
- Mar 2026 โ Page created. Sources: protocol.bryanjohnson.com, blueprint.bryanjohnson.com, ACSH review (Feb 2025), yourdailyway.com, omre.co, jinfiniti.com.
Sources
Compare Other Protocols
Key contrast: Attia is the most conservative (no NMN, skeptical of most longevity supplements). Sinclair is aggressive on NAD+/resveratrol. Johnson overlaps with Sinclair on NAD+ and goes furthest on experimental interventions. All three discontinued rapamycin or are cautious about it โ Johnson most visibly.
๐ Protocol Change Log
March 2026 โ Protocol page updated with latest publicly shared information.